Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of CT-2106 monotherapy in advanced metastatic ovarian cancer after platinum/taxane failure
2004-001457-28Phase 2Completed
- Sponsor
- CTI BioPharma
- Start
- Jan 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of polyglutamate camptothecin in ovarian cancer, sponsored by CTI BioPharma. Started Jan 2005; status: completed.
02
Drugs
polyglutamate camptothecin
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2004-001457-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001457-28.